 Sulfonamides
"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 1 | 1 | 2 | | 2002 | 5 | 0 | 5 | | 2003 | 3 | 1 | 4 | | 2004 | 4 | 2 | 6 | | 2005 | 5 | 4 | 9 | | 2006 | 7 | 7 | 14 | | 2007 | 3 | 3 | 6 | | 2008 | 7 | 3 | 10 | | 2009 | 6 | 2 | 8 | | 2010 | 8 | 4 | 12 | | 2011 | 11 | 7 | 18 | | 2012 | 7 | 7 | 14 | | 2013 | 8 | 5 | 13 | | 2014 | 11 | 7 | 18 | | 2015 | 9 | 10 | 19 | | 2016 | 6 | 5 | 11 | | 2017 | 8 | 5 | 13 | | 2018 | 9 | 11 | 20 | | 2019 | 10 | 5 | 15 | | 2020 | 8 | 11 | 19 | | 2021 | 3 | 5 | 8 | | 2022 | 1 | 15 | 16 | | 2023 | 0 | 18 | 18 | | 2024 | 10 | 6 | 16 | | 2025 | 4 | 8 | 12 | | 2026 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
-
Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.
-
Morgenstern DA, Barone G, Corradini N, Federico SM, Flotho C, Gerber NU, Khaw SL, Macy ME, Place AE, Vo KT, Badawi M, Chen X, Luo A, Rocco MA, Ross JA, Scherer F, Sunkersett G, Onishi M, Goldsmith KC. Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatr Blood Cancer. 2026 May; 73(5):e70178.
-
Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA. Tolerability and Outcomes With Serial Cycles of 28?Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. Am J Hematol. 2026 Apr; 101(4):728-735.
-
Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Clin Infect Dis. 2026 02 04; 81(6):1083-1090.
-
Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortüm KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026 01 20; 44(3):164-175.
-
Islam N, Dale JL, Reuben JS, Sapiah K, Coates JW, Markson FR, Zhang J, Wu L, Gasparetto M, Stevens BM, Staggs SE, Showers WM, Ransom MR, Desai J, Kulkarni UV, Engel KL, Jordan CT, Boyiadzis M, Smith CA. Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine. JCO Clin Cancer Inform. 2025 Dec; 9:e2400308.
-
Venkatasubramanian R, Mahoney SA, Hutton DA, VanDongen NS, Brunt VE, Greenberg NT, Longtine AG, Brandt L, Beyer AM, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment. Am J Physiol Heart Circ Physiol. 2025 12 01; 329(6):H1672-H1683.
-
La Vecchia S, Doshi S, Antonoglou P, Kundu T, Al Santli W, Avrampou K, Witkowski MT, Pellattiero A, Magrin F, Ames K, Verma A, Gritsman K, Su X, Mattarei A, Aifantis I, Scorrano L, Glytsou C. Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. Sci Adv. 2025 Oct 17; 11(42):eadx8662.
-
Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov. 2025 Sep 03; 6(5):437-449.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|